| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Mad Money Lightning Round,” Jim Cramer said KKR & Co. Inc. (NYSE:KKR) is a buy, adding that it is an “excellent firm, I've known them for years and years and years, and they have delivered time and time again.”
KKR said it will launch its tender offer for the common shares and share options of Fuji Soft.
Moderna, Inc. (NASDAQ:MRNA) is a “problem,” Cramer said. “They should be making money. They should have been able to do more with the money they had. They have not succeeded, they are losing money hand-over-fist. They have got to clean that up, or that stock is not going to rally.”
On Tuesday, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Moderna's updated COVID-19 vaccine, which targets the JN.1 variant of SARS-CoV-2.
“Give it a chance to come down,” Cramer said when asked about Lumen Technologies, Inc. (NYSE:LUMN). “It's a parabolic move, parabolic moves always destined to come down.”
On Sept. 3, Lumen announced exchange offers for unsecured notes of Lumen and Level 3.
The “Mad Money” host said Oklo Inc. (NYSE:OKLO) is a company that is again losing so much money “hand-over-fist I can't even look at it.”
On Aug. 13, Oklo reported a quarterly loss of $5.17 per share, versus a year-ago loss of 6 cents per share.
“Here's the problem with Coca-Cola (NYSE:KO): Straight up, way too far, way too fast,” Cramer said. “Doesn't work for me, let it come in.”
On Aug. 27, Morgan Stanley analyst Dara Mohsenian maintained Coca-Cola with an Overweight rating and raised the price target from $70 to $78.
Price Action:
Read Next:
Image Courtesy of Oklo, Inc.
